Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease

ABSTRACT:

SUBMITTER: Burmester G 

PROVIDER: S-EPMC12142088 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature